Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Acute Plasmodium Infection Promotes Interferon-Gamma-Dependent Resistance to Ebola Virus Infection.

Rogers KJ, Shtanko O, Vijay R, Mallinger LN, Joyner CJ, Galinski MR, Butler NS, Maury W.

Cell Rep. 2020 Mar 24;30(12):4041-4051.e4. doi: 10.1016/j.celrep.2020.02.104.

2.

TF protein of Sindbis virus antagonizes host type I interferon responses in a palmitoylation-dependent manner.

Rogers KJ, Jones-Burrage S, Maury W, Mukhopadhyay S.

Virology. 2020 Mar;542:63-70. doi: 10.1016/j.virol.2020.01.001. Epub 2020 Jan 7.

PMID:
32056669
3.

IL-4/IL-13 polarization of macrophages enhances Ebola virus glycoprotein-dependent infection.

Rogers KJ, Brunton B, Mallinger L, Bohan D, Sevcik KM, Chen J, Ruggio N, Maury W.

PLoS Negl Trop Dis. 2019 Dec 11;13(12):e0007819. doi: 10.1371/journal.pntd.0007819. eCollection 2019 Dec.

4.

TIM-1 serves as a receptor for Ebola virus in vivo, enhancing viremia and pathogenesis.

Brunton B, Rogers K, Phillips EK, Brouillette RB, Bouls R, Butler NS, Maury W.

PLoS Negl Trop Dis. 2019 Jun 26;13(6):e0006983. doi: 10.1371/journal.pntd.0006983. eCollection 2019 Jun.

5.

TIM1 (HAVCR1): an Essential "Receptor" or an "Accessory Attachment Factor" for Hepatitis A Virus?

Das A, Maury W, Lemon SM.

J Virol. 2019 May 15;93(11). pii: e01793-18. doi: 10.1128/JVI.01793-18. Print 2019 Jun 1. No abstract available.

6.

Biomechanical characterization of TIM protein-mediated Ebola virus-host cell adhesion.

Dragovich MA, Fortoul N, Jagota A, Zhang W, Schutt K, Xu Y, Sanabria M, Moyer DM Jr, Moller-Tank S, Maury W, Zhang XF.

Sci Rep. 2019 Jan 22;9(1):267. doi: 10.1038/s41598-018-36449-2.

7.

A 2'FY-RNA Motif Defines an Aptamer for Ebolavirus Secreted Protein.

Shubham S, Hoinka J, Banerjee S, Swanson E, Dillard JA, Lennemann NJ, Przytycka TM, Maury W, Nilsen-Hamilton M.

Sci Rep. 2018 Aug 17;8(1):12373. doi: 10.1038/s41598-018-30590-8.

8.

The role of mononuclear phagocytes in Ebola virus infection.

Rogers KJ, Maury W.

J Leukoc Biol. 2018 Oct;104(4):717-727. doi: 10.1002/JLB.4RI0518-183R. Epub 2018 Aug 10. Review.

PMID:
30095866
9.

TIM-1 Mediates Dystroglycan-Independent Entry of Lassa Virus.

Brouillette RB, Phillips EK, Patel R, Mahauad-Fernandez W, Moller-Tank S, Rogers KJ, Dillard JA, Cooney AL, Martinez-Sobrido L, Okeoma C, Maury W.

J Virol. 2018 Jul 31;92(16). pii: e00093-18. doi: 10.1128/JVI.00093-18. Print 2018 Aug 15.

10.

TIM1 (HAVCR1) Is Not Essential for Cellular Entry of Either Quasi-enveloped or Naked Hepatitis A Virions.

Das A, Hirai-Yuki A, González-López O, Rhein B, Moller-Tank S, Brouillette R, Hensley L, Misumi I, Lovell W, Cullen JM, Whitmire JK, Maury W, Lemon SM.

mBio. 2017 Sep 5;8(5). pii: e00969-17. doi: 10.1128/mBio.00969-17.

11.

Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.

Lennemann NJ, Herbert AS, Brouillette R, Rhein B, Bakken RA, Perschbacher KJ, Cooney AL, Miller-Hunt CL, Ten Eyck P, Biggins J, Olinger G, Dye JM, Maury W.

J Virol. 2017 Aug 10;91(17). pii: e00479-17. doi: 10.1128/JVI.00479-17. Print 2017 Sep 1.

12.

Mechanisms of Filovirus Entry.

Davey RA, Shtanko O, Anantpadma M, Sakurai Y, Chandran K, Maury W.

Curr Top Microbiol Immunol. 2017;411:323-352. doi: 10.1007/82_2017_14. Review.

PMID:
28601947
13.

Lentiviral Vectors Pseudotyped with Filoviral Glycoproteins.

Sinn PL, Coffin JE, Ayithan N, Holt KH, Maury W.

Methods Mol Biol. 2017;1628:65-78. doi: 10.1007/978-1-4939-7116-9_5.

14.

Production of Filovirus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus for Study of Filovirus Entry Mechanisms.

Brouillette RB, Maury W.

Methods Mol Biol. 2017;1628:53-63. doi: 10.1007/978-1-4939-7116-9_4.

PMID:
28573610
15.

Differences in Glycoprotein Complex Receptor Binding Site Accessibility Prompt Poor Cross-Reactivity of Neutralizing Antibodies between Closely Related Arenaviruses.

Brouillette RB, Phillips EK, Ayithan N, Maury W.

J Virol. 2017 Mar 13;91(7). pii: e01454-16. doi: 10.1128/JVI.01454-16. Print 2017 Apr 1.

16.

Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors.

Anantpadma M, Kouznetsova J, Wang H, Huang R, Kolokoltsov A, Guha R, Lindstrom AR, Shtanko O, Simeonov A, Maloney DJ, Maury W, LaCount DJ, Jadhav A, Davey RA.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4471-81. doi: 10.1128/AAC.00543-16. Print 2016 Aug.

17.

Characterization of Human and Murine T-Cell Immunoglobulin Mucin Domain 4 (TIM-4) IgV Domain Residues Critical for Ebola Virus Entry.

Rhein BA, Brouillette RB, Schaack GA, Chiorini JA, Maury W.

J Virol. 2016 Jun 10;90(13):6097-6111. doi: 10.1128/JVI.00100-16. Print 2016 Jul 1.

18.

Interferon-γ Inhibits Ebola Virus Infection.

Rhein BA, Powers LS, Rogers K, Anantpadma M, Singh BK, Sakurai Y, Bair T, Miller-Hunt C, Sinn P, Davey RA, Monick MM, Maury W.

PLoS Pathog. 2015 Nov 12;11(11):e1005263. doi: 10.1371/journal.ppat.1005263. eCollection 2015.

19.

Ebola virus entry into host cells: identifying therapeutic strategies.

Rhein BA, Maury WJ.

Curr Clin Microbiol Rep. 2015 Sep;2(3):115-124. Epub 2015 Jul 1.

20.

The Role of Conserved N-Linked Glycans on Ebola Virus Glycoprotein 2.

Lennemann NJ, Walkner M, Berkebile AR, Patel N, Maury W.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S204-9. doi: 10.1093/infdis/jiv201. Epub 2015 Jun 2.

21.

Ebola virus entry: a curious and complex series of events.

Moller-Tank S, Maury W.

PLoS Pathog. 2015 Apr 30;11(4):e1004731. doi: 10.1371/journal.ppat.1004731. eCollection 2015 Apr. Review. No abstract available.

22.

Phosphatidylserine receptors: enhancers of enveloped virus entry and infection.

Moller-Tank S, Maury W.

Virology. 2014 Nov;468-470:565-580. doi: 10.1016/j.virol.2014.09.009. Epub 2014 Sep 29. Review.

23.

TIM-family proteins inhibit HIV-1 release.

Li M, Ablan SD, Miao C, Zheng YM, Fuller MS, Rennert PD, Maury W, Johnson MC, Freed EO, Liu SL.

Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3699-707. doi: 10.1073/pnas.1404851111. Epub 2014 Aug 18.

24.

Characterizing functional domains for TIM-mediated enveloped virus entry.

Moller-Tank S, Albritton LM, Rennert PD, Maury W.

J Virol. 2014 Jun;88(12):6702-13. doi: 10.1128/JVI.00300-14. Epub 2014 Apr 2.

25.

Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.

Lennemann NJ, Rhein BA, Ndungo E, Chandran K, Qiu X, Maury W.

mBio. 2014 Jan 28;5(1):e00862-13. doi: 10.1128/mBio.00862-13.

26.

Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry.

Moller-Tank S, Kondratowicz AS, Davey RA, Rennert PD, Maury W.

J Virol. 2013 Aug;87(15):8327-41. doi: 10.1128/JVI.01025-13. Epub 2013 May 22.

27.

BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1).

Jones PH, Maric M, Madison MN, Maury W, Roller RJ, Okeoma CM.

Virology. 2013 Mar 30;438(1):37-49. doi: 10.1016/j.virol.2013.01.010. Epub 2013 Feb 12.

28.

Intrapulmonary Versus Nasal Transduction of Murine Airways With GP64-pseudotyped Viral Vectors.

Oakland M, Maury W, McCray PB Jr, Sinn PL.

Mol Ther Nucleic Acids. 2013 Jan 29;2:e69. doi: 10.1038/mtna.2012.60.

29.

AMP-activated protein kinase is required for the macropinocytic internalization of ebolavirus.

Kondratowicz AS, Hunt CL, Davey RA, Cherry S, Maury WJ.

J Virol. 2013 Jan;87(2):746-55. doi: 10.1128/JVI.01634-12. Epub 2012 Oct 31.

30.

Filovirus entry: a novelty in the viral fusion world.

Hunt CL, Lennemann NJ, Maury W.

Viruses. 2012 Feb;4(2):258-75. doi: 10.3390/v4020258. Epub 2012 Feb 7. Review.

31.

Ebolavirus: a brief review of novel therapeutic targets.

Kondratowicz AS, Maury WJ.

Future Microbiol. 2012 Jan;7(1):1-4. doi: 10.2217/fmb.11.110. Review. No abstract available.

32.

Transcutaneous DNA immunization following waxing-based hair depilation.

Sloat BR, Kiguchi K, Xiao G, DiGiovanni J, Maury W, Cui Z.

J Control Release. 2012 Jan 10;157(1):94-102. doi: 10.1016/j.jconrel.2011.08.038. Epub 2011 Sep 1.

33.

T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus.

Kondratowicz AS, Lennemann NJ, Sinn PL, Davey RA, Hunt CL, Moller-Tank S, Meyerholz DK, Rennert P, Mullins RF, Brindley M, Sandersfeld LM, Quinn K, Weller M, McCray PB Jr, Chiorini J, Maury W.

Proc Natl Acad Sci U S A. 2011 May 17;108(20):8426-31. doi: 10.1073/pnas.1019030108. Epub 2011 May 2.

34.

Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein.

Brindley MA, Hunt CL, Kondratowicz AS, Bowman J, Sinn PL, McCray PB Jr, Quinn K, Weller ML, Chiorini JA, Maury W.

Virology. 2011 Jul 5;415(2):83-94. doi: 10.1016/j.virol.2011.04.002. Epub 2011 May 6.

35.

Inhibition of HIV-1 infection by aqueous extracts of Prunella vulgaris L.

Oh C, Price J, Brindley MA, Widrlechner MP, Qu L, McCoy JA, Murphy P, Hauck C, Maury W.

Virol J. 2011 Apr 23;8:188. doi: 10.1186/1743-422X-8-188.

36.

Synthesis of chroman aldehydes that inhibit HIV.

Kraus GA, Mengwasser J, Maury W, Oh C.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1399-401. doi: 10.1016/j.bmcl.2011.01.031. Epub 2011 Jan 14.

37.

The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus.

Hunt CL, Kolokoltsov AA, Davey RA, Maury W.

J Virol. 2011 Jan;85(1):334-47. doi: 10.1128/JVI.01278-09. Epub 2010 Nov 3.

38.

Hypericum in infection: Identification of anti-viral and anti-inflammatory constituents.

Birt DF, Widrlechner MP, Hammer KD, Hillwig ML, Wei J, Kraus GA, Murphy PA, McCoy J, Wurtele ES, Neighbors JD, Wiemer DF, Maury WJ, Price JP.

Pharm Biol. 2009;47(8):774-782.

39.

Rho GTPases modulate entry of Ebola virus and vesicular stomatitis virus pseudotyped vectors.

Quinn K, Brindley MA, Weller ML, Kaludov N, Kondratowicz A, Hunt CL, Sinn PL, McCray PB Jr, Stein CS, Davidson BL, Flick R, Mandell R, Staplin W, Maury W, Chiorini JA.

J Virol. 2009 Oct;83(19):10176-86. doi: 10.1128/JVI.00422-09. Epub 2009 Jul 22.

40.

Identification of light-independent inhibition of human immunodeficiency virus-1 infection through bioguided fractionation of Hypericum perforatum.

Maury W, Price JP, Brindley MA, Oh C, Neighbors JD, Wiemer DF, Wills N, Carpenter S, Hauck C, Murphy P, Widrlechner MP, Delate K, Kumar G, Kraus GA, Rizshsky L, Nikolau B.

Virol J. 2009 Jul 13;6:101. doi: 10.1186/1743-422X-6-101.

41.

Inhibition of lentivirus replication by aqueous extracts of Prunella vulgaris.

Brindley MA, Widrlechner MP, McCoy JA, Murphy P, Hauck C, Rizshsky L, Nikolau B, Maury W.

Virol J. 2009 Jan 20;6:8. doi: 10.1186/1743-422X-6-8.

42.

An equine infectious anemia virus variant superinfects cells through novel receptor interactions.

Brindley MA, Zhang B, Montelaro RC, Maury W.

J Virol. 2008 Oct;82(19):9425-32. doi: 10.1128/JVI.01142-08. Epub 2008 Jul 30.

43.

Development and characterization of an equine infectious anemia virus Env-pseudotyped reporter virus.

Tallmadge RL, Brindley MA, Salmans J, Mealey RH, Maury W, Carpenter S.

Clin Vaccine Immunol. 2008 Jul;15(7):1138-40. doi: 10.1128/CVI.00088-08. Epub 2008 Apr 30.

44.

Echinacea in infection.

Birt DF, Widrlechner MP, Lalone CA, Wu L, Bae J, Solco AK, Kraus GA, Murphy PA, Wurtele ES, Leng Q, Hebert SC, Maury WJ, Price JP.

Am J Clin Nutr. 2008 Feb;87(2):488S-92S.

45.

Equine infectious anemia virus entry occurs through clathrin-mediated endocytosis.

Brindley MA, Maury W.

J Virol. 2008 Feb;82(4):1628-37. Epub 2007 Dec 5.

46.

Enhanced gene expression conferred by stepwise modification of a nonprimate lentiviral vector.

Sinn PL, Goreham-Voss JD, Arias AC, Hickey MA, Maury W, Chikkanna-Gowda CP, McCray PB Jr.

Hum Gene Ther. 2007 Dec;18(12):1244-52.

PMID:
18052720
47.

Drug induced superinfection in HIV and the evolution of drug resistance.

Leontiev VV, Maury WJ, Hadany L.

Infect Genet Evol. 2008 Jan;8(1):40-50. Epub 2007 Sep 29.

PMID:
18024234
48.
49.

Manipulation of P-TEFb control machinery by HIV: recruitment of P-TEFb from the large form by Tat and binding of HEXIM1 to TAR.

Sedore SC, Byers SA, Biglione S, Price JP, Maury WJ, Price DH.

Nucleic Acids Res. 2007;35(13):4347-58. Epub 2007 Jun 18.

50.

Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events.

Brindley MA, Hughes L, Ruiz A, McCray PB Jr, Sanchez A, Sanders DA, Maury W.

J Virol. 2007 Jul;81(14):7702-9. Epub 2007 May 2.

Supplemental Content

Support Center